Comparison
Dulaglutide vs. Bremelanotide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Research other
CAS no.
923950-08-7
189691-06-3
Molecular weight
59670 g/mol
1025.18 g/mol
Half-life
110 h
2.7 h
Sequence
GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-FcAc-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OHMechanism of action
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Bremelanotide
Bremelanotide is a cyclic peptide that binds non-selectively to melanocortin receptors (MC1R through MC5R) — with highest affinity at MC4R in the central nervous system. The precise role of MC4R activation in sexual behaviour is not fully understood; animal data show effects on hypothalamic circuits. Peripheral effects (blood pressure, hyperpigmentation) are attributed to MC1R/MC2R.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
5
of which in humans
5
5
Effects recorded
3
3
Open conflicts
0
0
Documented adverse events
2
2